VV116 for COVID-19
VV116 has been reported as potentially beneficial for treatment of COVID-19. We have not reviewed these studies. See all other treatments.
VV116 versus Nirmatrelvir–Ritonavir for Oral Treatment of Covid-19, New England Journal of Medicine, doi:10.1056/NEJMoa2208822 ,
VV116 as a potential treatment for COVID-19, Expert Opinion on Pharmacotherapy, doi:10.1080/14656566.2023.2193668 ,
Small-molecule anti-COVID-19 drugs and a focus on China’s homegrown mindeudesivir (VV116), Frontiers of Medicine, doi:10.1007/s11684-023-1037-3 ,
Current state-of-the-art and potential future therapeutic drugs against COVID-19, Frontiers in Cell and Developmental Biology, doi:10.3389/fcell.2023.1238027 ,
The novel coronavirus disease (COVID-19) continues to endanger human health, and its therapeutic drugs are under intensive research and development. Identifying the efficacy and toxicity of drugs in animal models is helpful for further screening of effective medications, which is also a prerequisite for drugs to enter clinical trials. Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) invades host cells mainly by the S protein on its surface. After the SARS-CoV-2 RNA genome is injected into the cells, M protein will help assemble and release new viruses. RdRp is crucial for virus replication, assembly, and release of new virus particles. This review analyzes and discusses 26 anti-SARS-CoV-2 drugs based on their mechanism of action, effectiveness and safety in different animal models. We propose five drugs to be the most promising to enter the next stage of clinical trial research, thus providing a reference for future drug development.
Bench-to-bedside: Innovation of small molecule anti-SARS-CoV-2 drugs in China, European Journal of Medicinal Chemistry, doi:10.1016/j.ejmech.2023.115503 ,
Repurposing clinically available drugs and therapies for pathogenic targets to combat SARS‐CoV‐2, MedComm, doi:10.1002/mco2.254 ,
Potential RNA-dependent RNA polymerase inhibitors as prospective drug candidates for SARS-CoV-2, European Journal of Medicinal Chemistry, doi:10.1016/j.ejmech.2023.115292 ,
An update on inhibitors targeting RNA-dependent RNA polymerase for COVID-19 treatment: Promises and challenges, Biochemical Pharmacology, doi:10.1016/j.bcp.2022.115279 ,
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.